Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world  

作　　者：GAO Qingyan 高清妍(State Key Lab,Experiment Hematol,Natl Clin Blood Dis Res Center,Haihe Cell Ecosys Lab,Instit Hematol&Blood Dis Hosp,CAMS&PUMC,Tianjin 300020,China)

机构地区：[1]State Key Lab,Experiment Hematol,Natl Clin Blood Dis Res Center,Haihe Cell Ecosys Lab,Instit Hematol&Blood Dis Hosp,CAMS&PUMC,Tianjin 300020,China

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第3期186-186,共1页中国医学文摘（内科学分册英文版）

摘　　要：Objective To investigate the efficacy and safety of combining venetoclax (VEN) with hypomethylated drugs(HMA) in the treatment of higher-risk (IPSS-R score>3.5) myelodysplastic syndromes(MDS).Methods From March 2021 to December 2022,forty-five MDS patients with intermediate and high risk were treated with VEN in combination with HMAs.

关 键 词：DRUGS TREATMENT IPSS MDS 

分 类 号：R551.3[医药卫生—血液循环系统疾病]